摘要 |
Thiazolidinedione (TZD) and its pharmacologically active derivatives can be used, in combination with agonists of glucagon-like peptide-1 (GLP-1), to treat non-insulin dependent diabetes mellitus, optionally with other therapies, by improving glycemic control while minimizing side effects, such as heart hypertrophy and elevated fed-state plasma glucose, which are associated with both TZD and GLP-1 monotherapies. Thus, the co-administration of TZD and GLP-1 helps regulate glucose homeostasis in Type II diabetic patients.
|
申请人 |
ELI LILLY AND COMPANY;YAKUBU-MADUS, FATIMA, EMITSEL;STRAMM, LAWRENCE, E.;JOHNSON, WILLIAM, T.;VIGNATI, LOUIS |
发明人 |
YAKUBU-MADUS, FATIMA, EMITSEL;STRAMM, LAWRENCE, E.;JOHNSON, WILLIAM, T.;VIGNATI, LOUIS |